Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
danoprevir + peginterferon alfa-2a + ribavirin
- Development stage
- Unknown
- Lead developer
- Ascletis Pharma
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral (danoprevir And Ribavirin), Subcutaneous (peginterferon Alfa-2a)
01
Overview
**Danoprevir + peginterferon alfa-2a + ribavirin** is a triple-drug combination therapy used to treat *chronic hepatitis C virus (HCV) genotype 1 infection*. Danoprevir is a potent, second-generation hepatitis C virus NS3/4A protease inhibitor that blocks viral replication. Peginterferon alfa-2a is a pegylated interferon that stimulates an antiviral immune response, while ribavirin is a nucleoside analogue with broad-spectrum antiviral activity. This combination has been shown to produce high rates of sustained virologic response (SVR) and is considered more effective than dual therapy with peginterferon alfa-2a and ribavirin alone[1][3][5].
- Brand names
- Pegasys
- Other names
- danoprevirpeginterferon alfa-2aribavirin
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)HCV RNA (Hepatitis C virus RNA)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on danoprevir + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on danoprevir + peginterferon alfa-2a + ribavirin.